Journal of Nuclear Medicine · 2022 · 48 citations · 23 references
MedicineNuclear MedicineOncologyOncologic Nuclear MedicinePharmacokinetics Of Anticancer AgentsTherapeutic Nuclear MedicineLigand BindingProstate CancerProstate Cancer Radioligand TherapyRadiation Therapy For Prostate DiseaseRadiopharmaceutical DesignTargeted Therapy PharmacokineticsLu-177 LabelingProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen RadioligandsPsma Targeting LigandsPsma-targeted TherapyRadioligand PharmacokineticsTumor Uptake KineticsTumor-targeted Ligands
The prostate-specific membrane antigen (PSMA)–targeted radiohybrid (rh) ligand [<sup>177</sup>Lu]Lu-rhPSMA-7.3 has recently been assessed in a pretherapeutic dosimetry study on prostate cancer patients. In comparison to [<sup>177</sup>Lu]Lu-PSMA I&T, application of [<sup>177</sup>Lu]Lu-rhPSMA-7.3 resulted in a significantly improved tumor dose but also higher kidney accumulation. Although rhPSMA-7.3 has been initially selected as the lead compound for diagnostic application based on the characterization of its gallium complex, a systematic comparison of the most promising <sup>177</sup>Lu-labeled rhPSMA ligands is still missing. Thus, this study aimed to identify the rhPSMA ligand with the most favorable pharmacokinetics for <sup>177</sup>Lu-radioligand therapy. <b>Methods:</b> The 4 isomers of [<sup>177</sup>Lu]Lu-rhPSMA-7 (namely [<sup>177</sup>Lu]Lu-rhPSMA-7.1, -7.2, -7.3, and -7.4), along with the novel radiohybrid ligands [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and -10.2, were compared with the state-of-the-art compounds [<sup>177</sup>Lu]Lu-PSMA I&T and [<sup>177</sup>Lu]Lu-PSMA-617. The comparative evaluation comprised affinity studies (half-maximal inhibitory concentration) and internalization experiments on LNCaP cells, as well as lipophilicity measurements. In addition, we determined the apparent molecular weight (AMW) of each tracer as a parameter for human serum albumin (HSA) binding. Biodistribution studies and small-animal SPECT imaging were performed on LNCaP-tumor bearing mice at 24 h after injection. <b>Results:</b><sup>177</sup>Lu labeling of the radiohybrids was performed according to the established procedures for the currently established PSMA-targeted ligands. All ligands showed potent binding to PSMA-expressing LNCaP cells, with affinities in the low nanomolar range and high internalization rates. Surprisingly, the most pronounced differences regarded the HSA-related AMW. Although [<sup>177</sup>Lu]Lu-rhPSMA-7 isomers demonstrated the highest AMW and thus strongest HSA interactions, [<sup>177</sup>Lu]Lu-rhPSMA-10.1 showed an AMW lower than for [<sup>177</sup>Lu]Lu-rhPSMA-7.3 but higher than for the <sup>177</sup>Lu-labeled references PSMA I&T and PSMA-617. In biodistribution studies, [<sup>177</sup>Lu]Lu-rhPSMA-10.1 exhibited the lowest kidney uptake and fastest excretion from the blood pool of all rhPSMA ligands while preserving a high tumor accumulation. <b>Conclusion:</b> Clinical investigation of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 is highly warranted to determine whether the favorable pharmacokinetics observed in mice will also result in high tumor uptake and decreased absorbed dose to kidneys and other nontarget tissues in patients.
23
Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations
Medicine, Nuclear Medicine, Oncology +14
Martina Benešová, Martin Schäfer, Ulrike Bauder‐Wüst et al. · Journal of Nuclear Medicine · 2015 · 594 citations
Martina Weineisen, Margret Schottelius, Jakub Šimeček et al. · Journal of Nuclear Medicine · 2015 · 532 citations · Full text
Medicine, Oncology, Pharmacology +17
John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 486 citations · Full text
Medicine, Nuclear Medicine, Oncology +17